Charles Schwab Investment Management Inc. Has $3.11 Million Stock Position in Celcuity Inc. (NASDAQ:CELC)

Charles Schwab Investment Management Inc. lifted its stake in Celcuity Inc. (NASDAQ:CELC) by 7.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 237,706 shares of the company’s stock after buying an additional 16,035 shares during the period. Charles Schwab Investment Management Inc. owned about 0.64% of Celcuity worth $3,112,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Acuta Capital Partners LLC boosted its stake in shares of Celcuity by 3.6% in the 3rd quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock valued at $695,000 after purchasing an additional 1,600 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Celcuity by 14.9% during the 4th quarter. New York State Common Retirement Fund now owns 28,391 shares of the company’s stock valued at $372,000 after purchasing an additional 3,682 shares during the last quarter. Rhumbline Advisers boosted its position in Celcuity by 20.6% in the fourth quarter. Rhumbline Advisers now owns 38,755 shares of the company’s stock valued at $507,000 after buying an additional 6,625 shares in the last quarter. SG Americas Securities LLC grew its stake in Celcuity by 83.2% during the fourth quarter. SG Americas Securities LLC now owns 14,646 shares of the company’s stock worth $192,000 after buying an additional 6,651 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Celcuity by 20.3% during the fourth quarter. Bank of New York Mellon Corp now owns 64,125 shares of the company’s stock worth $839,000 after buying an additional 10,828 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Stock Up 1.0 %

NASDAQ:CELC opened at $10.54 on Friday. The company has a market cap of $391.35 million, a price-to-earnings ratio of -4.04 and a beta of 0.65. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The stock’s fifty day moving average price is $11.21 and its two-hundred day moving average price is $13.01. Celcuity Inc. has a 52-week low of $8.53 and a 52-week high of $22.19.

Analyst Ratings Changes

Separately, Needham & Company LLC boosted their target price on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $30.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.